Cannabichromene (CBC) is the sixth most researched of the minor cannabinoids and may have some positive therapeutic effects. Often found in full-spectrum CBD products, it is one of the cannabinoids that work to help bring about the famed entourage effect.
It does not produce any of the psychoactive properties that THC does and is thought to bind indirectly with the endocannabinoid system through our own naturally occurring cannabinoids, primarily anandamide and 2-AG. It is also a possible agonist to the TRPA1 and TRPV1 receptors. These receptors control temperature, inflammation, and sensitivity to pain. It is not understood completely how or if it binds with CB1 or CB2 receptors.
In most cannabis plants, CBC is found in low-levels and seems to be most effective when combined with other cannabinoids. Though research on this cannabinoid is limited, what we know so far is promising. The British Journal of Pharmacology has undergone several studies involving the compound, including an animal study showing that it works to relieve inflammation. Several other projects suggest CBC could potentially help with addiction, anxiety, depression, pain, cancer, and even bacterial and fungal infections, including those that are antibiotic resistant.
CBC is present in varying amounts in many CBD products, and with more research, it is expected to be an essential part of medical marijuana therapy in the future.